Table 2. Correlation between RBMX expression and clinicopathologic parameters of patients with esophageal cancer.
| Clinical features | Level | IOD high (n=27) | IOD low (n=26) | χ2 | P |
|---|---|---|---|---|---|
| Gender (%) | Male | 17 (63.0) | 18 (69.2) | 0.232 | 0.63 |
| Female | 10 (37.0) | 8 (30.8) | |||
| Age, years, median [IQR] | 57 [37, 78] | 60 [48, 75] | 23.79 | 0.474 | |
| Distant metastatic site (%) | No | 24 (88.9) | 25 (96.2) | 1.002 | 0.317 |
| Yes | 3 (11.1) | 1 (3.8) | |||
| Pathological grading (%) | I | 0 (0.0) | 3 (11.5) | 4.283 | 0.369 |
| II | 22 (81.5) | 18 (69.2) | |||
| III | 5 (18.5) | 5 (19.2) | |||
| Pathological morphology (%) | Not classified | 3 (11.1) | 2 (7.7) | 2.963 | 0.813 |
| Infiltrating ulcer type | 2 (7.4) | 1 (3.8) | |||
| Ulcerative type | 13 (48.1) | 14 (53.8) | |||
| Uplift type | 6 (22.2) | 7 (26.9) | |||
| Basin type | 1 (3.7) | 0 (0.0) | |||
| Constricted type | 1 (3.7) | 2 (7.7) | |||
| Mushroom type | 1 (3.7) | 0 (0.0) | |||
| Total lymph nodes, median [IQR] | 12 [1, 30] | 20 [3, 35] | 22.902 | 0.69 | |
| Positive lymph node, median [IQR] | 1 [0, 16] | 0 [0, 7] | 9.035 | 0.339 | |
| T (%) | Not classified | 1 (3.7) | 6 (23.1) | 6.072 | 0.194 |
| T1 | 1 (3.7) | 0 (0.0) | |||
| T2 | 6 (22.2) | 4 (15.4) | |||
| T3 | 18 (66.7) | 16 (61.5) | |||
| T4a | 1 (3.7) | 0 (0.0) | |||
| N (%) | Not classified | 0 (0.0) | 2 (7.7) | 4.43 | 0.351 |
| N0 | 13 (48.1) | 14 (53.8) | |||
| N1 | 6 (22.2) | 7 (26.9) | |||
| N2 | 6 (22.2) | 2 (7.7) | |||
| N3 | 2 (7.4) | 1 (3.8) | |||
| M (%) | M0 | 24 (88.9) | 25 (96.2) | 1.002 | 0.317 |
| M1 | 3 (11.1) | 1 (3.8) |
RBMX, RNA binding motif protein X-linked; IOD, integrated optical density; IQR, interquartile range.